Drugs / Novo Helisen Depot
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00263549 | Sep 2002 → Feb 2005 | house allergic alveolitis | Allergopharma GmbH & Co. KG | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT00540150 Comparator | May 2004 → Mar 2005 | — | Johann Wolfgang Goethe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06778213 Comparator | Nov 2024 → Apr 2026 overdue | allergic disease | Wroclaw Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT00496574 Comparator | May 2006 → Nov 2013 | asthma | Medical University of Lodz | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novo Helisen Depot | “The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis” NCT00263549 ↗ |
| Modality | Other / unclassified | “Depot House Dust Mite Allergen Extract” NCT00263549 ↗ |
| Route | Subcutaneous | “subcutaneous immunotherapy” NCT00496574 ↗ |